EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Emerging biomarkers for Parkinson's disease in biological fluids

Petra Bago Rožanković, Goran Šimić

Frontiers in Aging Neuroscience · 13.07.2026 · 18

DOI: 10.3389/fnagi.2026.1835751 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Aging Neuroscience, online erschienen am 13.07.2026. Verfasst von Petra Bago Rožanković und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, University Hospital Dubrava, Avenija Gojka Šuška, Zagreb, Croatia. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 255 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Early and accurate diagnosis of Parkinson's disease (PD) remains a challenge, hindering the efficient recruitment of patients into clinical trials aimed at disease modification. This underscores the urgent need for validated and clinically applicable biomarkers. Research continues to expand our knowledge of fluid biomarkers for detecting and monitoring PD progression. Cerebrospinal fluid α-synuclein (α-syn) seed amplification assays (SAA) have emerged as highly sensitive and specific biomarkers for the diagnosis of PD. The development of less invasive procedures using biological fluids such as serum or saliva would be more practical for routine clinical use. Recent data demonstrate the presence of pathogenic α-synuclein in the serum of PD patients compared with healthy controls, detected using real-time quaking-induced conversion (RT-QuIC) assays. Elevated ratios of pS129-α-syn and/or oligomeric α-syn to total α-syn have also been reported in PD. Future research should clarify differences in protein aggregate formation across various synucleinopathies. Promising advances toward a clinically useful blood-based diagnostic test for PD include the quantification of proteins released from neural-derived extracellular vesicles (NDEVs), such as oligomeric and phosphorylated α-syn, tau, and disease-associated microRNAs. Given the role of neuroinflammation in PD pathogenesis, inflammatory biomarkers, including interleukin (IL)-6, IL-10, tumor necrosis factor-α(TNF-α), glial fibrillary acidic protein (GFAP), chitinase-3-like protein 1 (YKL-40), and monocyte chemoattractant protein-1 (MCP-1), are under active investigation. Furthermore, fluid biomarkers associated with Alzheimer's disease pathology are being explored for their potential to predict motor and cognitive decline in PD and related synucleinopathies. Salivary EVs hold promise as a non-invasive source of PD biomarkers; however, robust validation in large, well-characterized cohorts is essential to improve the diagnostic and prognostic accuracy of PD.

Schlagwörter

Stichwörter der Autor:innen

Alzheimer's disease biomarkersParkinson's diseaseextracellular vesiclesneuroinflammationseed amplification assays (SAA)α-synuclein

Autor:innen und Institutionen

  • Department of Neurology, University Hospital Dubrava, Avenija Gojka Šuška, Zagreb, Croatia.
  • School of Medicine, Catholic University of Croatia, Ilica, Zagreb, Croatia.
  • Department of Neuroscience, Croatian Institute for Brain Research, University of Zagreb School of Medicine, Šalata, Zagreb, Croatia.

Zitieren

APA

Bago Rožanković, P., & Šimić, G. (2026). Emerging biomarkers for Parkinson's disease in biological fluids. Frontiers in Aging Neuroscience, 18. https://doi.org/10.3389/fnagi.2026.1835751

Vancouver

Bago Rožanković P, Šimić G. Emerging biomarkers for Parkinson's disease in biological fluids. Frontiers in Aging Neuroscience. 2026;18. doi:10.3389/fnagi.2026.1835751

BibTeX
@article{BagoRoankovi2026,
  author = {Bago Rožanković, Petra and Šimić, Goran},
  title = {Emerging biomarkers for Parkinson's disease in biological fluids},
  journal = {Frontiers in Aging Neuroscience},
  year = {2026},
  volume = {18},
  doi = {10.3389/fnagi.2026.1835751}
}
Kostenlos starten →